310 related articles for article (PubMed ID: 35811392)
21. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J
Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938
[TBL] [Abstract][Full Text] [Related]
22. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
Zhang W; Shi F; Kong Y; Li Y; Sheng C; Wang S; Wang Q
Cancer Med; 2022 Feb; 11(3):676-691. PubMed ID: 34862763
[TBL] [Abstract][Full Text] [Related]
23. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
[TBL] [Abstract][Full Text] [Related]
24. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
25. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Chen X; Fang L; Zhu Y; Bao Z; Wang Q; Liu R; Sun W; Du H; Lin J; Yu B; Chen S; Zhou J; Zhou J
Cancer Immunol Immunother; 2021 Dec; 70(12):3513-3524. PubMed ID: 33899131
[TBL] [Abstract][Full Text] [Related]
26. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
27. Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer.
Zhou J; Bao M; Gao G; Cai Y; Wu L; Lei L; Zhao J; Ji X; Huang Y; Su C
BMC Med; 2022 Jul; 20(1):256. PubMed ID: 35902848
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
29. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
30. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
Front Immunol; 2022; 13():834142. PubMed ID: 35242138
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
32. Deciphering radiological stable disease to immune checkpoint inhibitors.
Luo J; Wu S; Rizvi H; Zhang Q; Egger JV; Osorio JC; Schoenfeld AJ; Plodkowski AJ; Ginsberg MS; Callahan MK; Maher C; Shoushtari AN; Postow MA; Voss MH; Kotecha RR; Gupta A; Raja R; Kris MG; Hellmann MD
Ann Oncol; 2022 Aug; 33(8):824-835. PubMed ID: 35533926
[TBL] [Abstract][Full Text] [Related]
33. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
34. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.
Fang W; Ma Y; Yin JC; Hong S; Zhou H; Wang A; Wang F; Bao H; Wu X; Yang Y; Huang Y; Zhao H; Shao YW; Zhang L
Clin Cancer Res; 2019 Aug; 25(16):5015-5026. PubMed ID: 31085721
[TBL] [Abstract][Full Text] [Related]
36. Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.
Huang RSP; Carbone DP; Li G; Schrock A; Graf RP; Zhang L; Murugesan K; Ross JS; Tolba K; Sands J; Oxnard GR; Spigel D
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650021
[TBL] [Abstract][Full Text] [Related]
37. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
[TBL] [Abstract][Full Text] [Related]
38. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
39. A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients.
Hu X; Guo J; Shi J; Li D; Li X; Zhao W
BMC Pulm Med; 2023 Jun; 23(1):223. PubMed ID: 37349743
[TBL] [Abstract][Full Text] [Related]
40. EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.
Bai H; Duan J; Li C; Xie W; Fang W; Xu Y; Wang G; Wan R; Sun J; Xu J; Wang X; Fei K; Zhao Z; Cai S; Zhang L; Wang J; Wang Z
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33303576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]